Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

PREDICT v3.0

PREDICT v3.0Adjuvant Therapy Benefit Framework

Absolute Benefit Tier

Model Inputs

The PREDICT model integrates age, tumor size, grade, nodal status, ER/PR, HER2, Ki67, and mode of detection to calculate 5-, 10-, and 15-year survival probabilities.

Therapeutic Impact

Modest Benefit

Clinical Strategy

Modest absolute survival benefit. Treatment decision depends on shared risk/benefit discussion and patient preference.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Used during the initial multidisciplinary clinic to counsel newly diagnosed breast cancer patients.
Visualizes the 5-year, 10-year, and 15-year overall survival estimates.
Highly effective visual aid to show patients the exact, numerical absolute benefit (e.g., "Chemotherapy will add 3% to your 10-year survival") to aid in shared decision-making.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the Oncotype DX Recurrence, RCB (Residual Cancer Burden), Tyrer-Cuzick (IBIS v8) or the Tnm 8th Ed Breast Prognostic to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

IMWG Myeloma Frailty
ATA Thyroid Risk
Oncotype DX Recurrence
Lung-RADS v2022
iRECIST
Calvert Formula
ELN CML Milestones
FIGO 2021
Karnofsky Status
NCCN-IPI
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.